Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2215 Yukon Street VANCOUVER BC V5Y 0A1 |
Tel: | N/A |
Website: | https://www.abcellera.com |
IR: | See website |
Key People | ||
Carl L.G. Hansen Chairman of the Board, President, Chief Executive Officer, Co-Founder | Veronique Lecault Co-Founder, Chief Operating Officer, Director | Andrew Booth Chief Financial Officer |
Tryn T. Stimart Chief Compliance Officer, Corporate Secretary, Chief Legal Officer | Neil Aubuchon Chief Commercial Officer |
Business Overview |
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening. |
Financial Overview |
For the fiscal year ended 31 December 2023, AbCellera Biologics Inc revenues decreased 92% to $38M. Net loss totaled $146.4M vs. income of $158.5M. Revenues reflect Royalty revenue decrease from $443M to $0K, Research fees decrease of 13% to $35.6M. Net loss reflects Research and development - Balancing val increase of 72% to $143.9M (expense), Stock-based Compensation in R&D increase of 31% to $31.8M (expense). |
Employees: | 586 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $565.72M as of Dec 31, 2023 |
Annual revenue (TTM): | $38.03M as of Dec 31, 2023 |
EBITDA (TTM): | -$209.51M as of Dec 31, 2023 |
Net annual income (TTM): | -$146.40M as of Dec 31, 2023 |
Free cash flow (TTM): | -$121.38M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 292,782,152 as of Feb 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |